CBD Showed Promising but Inconclusive Heart Recovery Benefits in Acute Myocarditis Trial
In a 109-patient RCT, CBD did not meet primary cardiac endpoints in acute myocarditis, but significantly reduced left ventricular mass and showed an anti-inflammatory trend.
Quick Facts
What This Study Found
CBD (up to 10 mg/kg BID for 12 weeks) did not significantly improve ECV (p=0.054) or GLS (p=0.90). LV mass was significantly reduced (-9.2g, p=0.012). LAESV decreased (-8.1 ml, p=0.038). 100% completion rate.
Key Numbers
109 patients, 100% completion. ECV: -3.7 ml (p=0.054). LV mass: -9.2g (p=0.012). LAESV: -8.1 ml (p=0.038). GLS: -0.1 (p=0.90).
How They Did This
ARCHER Study: multicenter double-blind placebo-controlled phase 2 trial. 109 patients with CMR-confirmed acute myocarditis. 56 CBD, 53 placebo for 12 weeks.
Why This Research Matters
First RCT of CBD in cardiac inflammation. While primary endpoints were missed, secondary findings suggest anti-inflammatory cardiac effects worth investigating.
The Bigger Picture
The near-significant ECV and significant LV mass reduction provide biological plausibility for CBD's cardiac anti-inflammatory effects.
What This Study Doesn't Tell Us
Primary endpoints not met. Mild-moderate myocarditis with preserved LV function at baseline. Small sample. Phase 2.
Questions This Raises
- ?Would a larger trial reach ECV significance?
- ?Would CBD help more in severe myocarditis?
- ?Could it prevent progression to cardiomyopathy?
Trust & Context
- Key Stat:
- Significant LV mass reduction (-9.2g, p=0.012) but primary endpoints missed
- Evidence Grade:
- Well-designed international RCT with 100% completion, but primary endpoints not met.
- Study Age:
- 2026 study
- Original Title:
- Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study.
- Published In:
- ESC heart failure, 13(1) (2026)
- Authors:
- McNamara, Dennis M, Cooper, Leslie T, Friedrich, Matthias G, Arbel, Yaron, Bhimaraj, Arvind, Bocchi, Edimar, Hamer, Andrew, Herdy, Artur Haddad, Kerneis, Mathieu, Liu, Peter P, Parker, Andrea B, Pocock, Stuart J, Smith, Eldon R, Tang, W H Wilson, Torre-Amione, Guillermo, Tschöpe, Carsten
- Database ID:
- RTHC-08479
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
Did CBD help with myocarditis?
Primary markers did not significantly improve (p=0.054 for ECV). The significant LV mass reduction suggests some anti-inflammatory benefit worth further study.
Is this the first heart CBD trial?
Yes. The ARCHER study is the first RCT of pharmaceutical CBD in cardiac inflammation.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08479APA
McNamara, Dennis M; Cooper, Leslie T; Friedrich, Matthias G; Arbel, Yaron; Bhimaraj, Arvind; Bocchi, Edimar; Hamer, Andrew; Herdy, Artur Haddad; Kerneis, Mathieu; Liu, Peter P; Parker, Andrea B; Pocock, Stuart J; Smith, Eldon R; Tang, W H Wilson; Torre-Amione, Guillermo; Tschöpe, Carsten. (2026). Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study.. ESC heart failure, 13(1). https://doi.org/10.1093/eschf/xvaf034
MLA
McNamara, Dennis M, et al. "Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study.." ESC heart failure, 2026. https://doi.org/10.1093/eschf/xvaf034
RethinkTHC
RethinkTHC Research Database. "Impact of cannabidiol on myocardial recovery in patients wit..." RTHC-08479. Retrieved from https://rethinkthc.com/research/mcnamara-2026-impact-of-cannabidiol-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.